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There are currently no regulatory approved pharmacological treatments for cognitive 
impairment associated with schizophrenia (CIAS). One possibility is that trial methodology 
itself is hindering their development. Emerging evidence suggests that patients with 
schizophrenia may show limited benefit from pro-cognitive interventions if they already 
exhibit intact cognitive performance, relative to normative thresholds. The aim of this report 
was to examine the extent to which objectively assessed cognitive performance has been 
used as an eligibility and/or stratification criterion in CIAS pharmacotherapy trials. On 16th 
January 2019, we conducted a systematic search of studies listed on ClinicalTrials.gov 
to identify randomized, double-blind, placebo-controlled, add-on pharmacotherapy trials 
conducted in patients with a diagnosis of schizophrenia, in which a paper-and-pencil or 
computerized cognitive task (or battery) was specified as a primary outcome measure. 
Of the 87 trials that met our inclusion criteria, 10 (11.5%) required the presence of an 
objectively assessed cognitive deficit as part of their patient eligibility criteria. No studies 
reported stratifying patients according to the presence or degree of cognitive impairment 
they exhibited. These results suggest that the vast majority of CIAS trials may have been 
underpowered due to the inclusion of cognitively “normal” patients. Purposive screening 
for cognitive impairment could increase CIAS trial success.
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INTRODUCTION
Cognitive impairment is common in people with schizophrenia and is among the strongest 
predictors of functional disability in this patient group (1–3). Despite considerable efforts and some 
initially promising results, there are currently no regulatory approved pharmacological treatments 
for cognitive impairment associated with schizophrenia (CIAS) (4, 5). It remains unclear, however, 
whether this is truly due to these compounds being ineffective, or whether trial methodology itself 
has been a limiting factor in successfully demonstrating the efficacy of these agents.
Schizophrenia is a heterogeneous disorder associated with varying clinical and cognitive 
profiles (6). Though the majority of patients with schizophrenia exhibit some general cognitive 
dysfunction compared to antecedent expectations, such as premorbid intelligence (7, 8), there is 
evidence that approximately a quarter of patients display cognitive performance comparable to 
healthy controls (9–12). Recent evidence has indicated that these “normally” performing patients 
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are significantly less likely to exhibit changes in cognition when 
participating in CIAS trials (13, 14), suggesting that inclusion of 
these individuals may limit the scope to detect a pro-cognitive 
efficacy signal. Contemporary evidence has also reported that 
there is no association between cognitive performance and 
measures of social, vocational or everyday functioning in these 
cognitively “normal” patients (15), suggesting that other illness-
related variables are the primary drivers of functional disability 
among these individuals. Given that cognition is thought to 
remain relatively stable following the first psychotic episode 
(11, 16), the rationale for including and administering an 
investigational medicinal product to this subset of “normally” 
performing patients is becoming increasingly unclear. Exclusion 
of these individuals, or at least identifying and ensuring equal 
stratification of these “normal” performers across trial arms 
during randomization, may provide additional power to observe 
pro-cognitive treatment effects, though it is currently unclear 
whether either of these approaches have been routinely adopted.
The aim of this report was to examine the extent to 
which objectively assessed cognitive performance has been 
used as an eligibility and/or stratification criterion in CIAS 
pharmacotherapy trials.
METHODS
On 16th January 2019, we conducted a systematic search of trials 
listed on ClinicalTrials.gov (since its inception) using the keyword 
“schizophrenia” (n = 2,978). Eligible studies were those recorded 
as randomized, double-blind, placebo-controlled, add-on 
pharmacotherapy trials conducted in patients with a diagnosis 
of schizophrenia, in which a paper-and-pencil or computerized 
cognitive task (or battery) was specified as a primary outcome 
measure. Phase 1 studies (which typically focus on drug 
safety), nutraceutical interventions (including pharmaceutical-
grade dietary supplements) and single-dose studies (including 
crossover trials) were excluded. We cross-referenced study 
information listed on ClinicalTrials.gov with corresponding 
published literature where this could be identified. For all eligible 
trials, information was manually extracted (where provided) on: 
i) study details; ii) cognition-related study eligibility criteria; iii) 
cognition-related stratification procedures or sensitivity analyses.
RESULTS
Of the 87 trials that met our inclusion criteria, 10 (11.5%) 
explicitly reported requiring the presence of an objectively 
measured cognitive deficit as part of their patient eligibility 
criteria (Table 1; Supplementary Table 1). In contrast, six 
trials (6.9%) screened and excluded individuals with very high 
cognitive performance in an effort to avoid ceiling effects, 
while the majority of trials excluded those with (or at increased 
risk of) severe cognitive impairments that could potentially 
confound cognitive testing, such as low IQ, neurological 
or developmental disorders or a history of head trauma. A 
number of the included studies also stratified patients during 
randomization according to factors that could potentially 
influence treatment response, such as their sex, recruiting site, 
genetic profile, tobacco use, or inpatient/outpatient status. 
However, we found no studies reporting the stratification 
of patients according to the presence or degree of cognitive 
impairment exhibited at screening or baseline. Similarly, we 
identified only a single study that listed an intention to perform 
post-trial sensitivity analyses to establish whether any pro-
cognitive effects were exclusive to those exhibiting cognitive 
impairment at baseline.
DISCUSSION
The vast majority of CIAS pharmacotherapy trials have not 
included formal eligibility criteria to ensure participants exhibit 
a cognitive deficit as part of their study screening procedures. 
While this is consistent with consensus guidelines that have 
previously recommended such an approach (4), the failure to 
develop any effective compounds, coupled with recent evidence 
suggesting that the inclusion of “normal” performers may 
limit the ability to detect pro-cognitive effects, has brought the 
rationale for this into question.
In the absence of purposive screening for cognitive impairment, 
an important next step is to clarify how many patients entering 
CIAS trials already perform within the limits of “normal” cognitive 
performance. Pooled cognitive data from 15 multi-site trials 
involving patients with schizophrenia (n = 2,616) has recently been 
published, including both composite and domain-specific baseline 
MATRICS Consensus Cognitive Battery (MCCB) T scores 
(17). These T scores are standardized to age and sex-matched 
normative data, and have an estimated mean of 50 and standard 
deviation of 10 in the general healthy population (18). While the 
individual patient-level data is unavailable, visual inspection of 
the associated histograms suggests MCCB scores from the pooled 
trial data were broadly normally distributed (17). This coupled 
with the published sample means and standard deviations allow 
inferences to be made regarding the proportion of patients that 
performed within different cut-offs of the healthy normative 
TABLE 1 | Eligible CIAS pharmacotherapy trials that listed an objectively measured cognitive deficit among their patient inclusion criteria.
Trial phase
(as listed on ClinicalTrials.gov)
Total Phase 2 Phase 2/3 Phase 3 Phase 4 Not reported
Number of eligible trials identified 87 46 2 9 19 11
Number requiring objectively assessed 
cognitive deficit for patient inclusion (%)
10 (11.5%) 6 (13%) 0 (0%) 0 (0%) 3 (15.8%) 1 (9.1%)
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mean. On this basis, it appears that a number of patients scored 
within the normative range across each of the cognitive domains, 
for example, approximately fifty percent of patients had a T score 
equal to or greater than 40 for the “problem solving” MCCB 
subscale. Though the trials included in these pooled analyses were 
not exclusively pro-cognitive pharmacotherapy trials, the patient 
eligibility criteria used across these studies reflected those typically 
used in CIAS trials. Further analyses of existing patient-level data 
would help to clarify what proportion of patients entering CIAS 
pharmacotherapy trials already exhibit cognitive performance 
comparable to healthy controls. This will be valuable in helping to 
guide decision making in future CIAS trial design.
For the purposes of demonstrating efficacy, pro-cognitive 
intervention trials should be powered to detect a “clinically 
meaningful” difference between treatment groups, typically 
equating to an effect size in the small-medium range (e.g., 
Cohen’s d ≥ 0.3). However, recent evidence has suggested that 
it is unlikely that one would expect to see gains in cognition 
this large in up to a quarter of patients who score similarly to 
healthy controls on cognitive tasks (9–13). This means that the 
poorer performing patients would need to exhibit substantially 
greater cognitive gains in order to meet the pre-specified 
average group-based level of improvement. Based on the results 
of our database search, it also indicates that the majority of 
CIAS trials have likely been underpowered to detect beneficial 
treatment effects.
An interesting parallel in schizophrenia-related clinical trial 
methodology can be drawn with the development of treatments 
for negative symptoms. Like cognitive impairment, these are 
a common and highly debilitating aspect of schizophrenia for 
which there are currently no regulatory approved treatments 
(19–21). However, at the time of writing, all ongoing phase 
2 and 3 trials listed on ClinicalTrials.gov in which a negative 
symptom measure is specified as the primary outcome, 
require that patients exhibit at least a moderate level of related 
symptomatology at screening and at baseline in order to be 
eligible for inclusion.
While it is more commercially practical and appealing to 
develop a treatment aimed at all patients within a diagnostic 
category, the substantial development costs involved, ever-
increasing unmet need for an effective CIAS treatment and 
growing movement towards precision psychiatry (matching 
the right drug to the right patient at the right time) may make 
cognitive screening in the context of CIAS trials a necessity. 
There is also an argument that exposing cognitively normal 
patients to these investigational drugs represents an unnecessary 
and unethical risk, particularly given that polypharmacy is 
already common among patients with schizophrenia (22). 
Cognitive screening has already been successfully adopted in a 
small number of CIAS trials and could be adapted for use in 
clinical practice (if necessary) using relatively simple and brief 
testing procedures as is routine in other indications, such as 
Alzheimer’s disease.
Practical considerations include the need to determine 
a consensus on suitable measures and thresholds for 
establishing a relevant level of cognitive impairment among 
patients with schizophrenia. Trials identified in our search 
used a range of tools and criteria to identify “impaired” 
patients (Supplementary Table 1), though a threshold ≥ 1 
standard deviation below the healthy normative mean on an 
objective cognitive task(s) would align with similar guidelines 
in other disease-areas, as well as recent studies investigating 
the impact of cognitive impairment on real-world functioning 
in schizophrenia (15, 23). There is also an argument that this 
should be based on the hypothesized mechanism of action of 
the study drug and the cognitive domains thought most likely 
to be enhanced. Whether to then exclude or stratify “normally” 
performing patients across study arms during randomization 
are also potentially important considerations in this field, 
while pre-planned subgroup analyses may provide a practical 
intermediate approach, particularly during early stages of 
drug development.
Though the focus of this article is on CIAS pharmacotherapy 
trials, cognitive screening in the context of pro-cognitive 
intervention studies is likely to have implications beyond 
schizophrenia. Cognitive dysfunction is an important target 
for therapeutic intervention across a range of psychiatric 
populations, though substantial heterogeneity is also evident in 
cognitive profiles within these diagnostic groups (24–26). Post 
hoc analyses of trials involving patients with mood disorders also 
suggest that individuals with an objectively assessed cognitive 
deficit at baseline are substantially more likely to exhibit a 
clinically relevant improvement post-treatment, relative to those 
with normal cognitive functioning (27). This has led to similar 
calls for the use of cognitive screening in clinical trials to ensure 
the inclusion of only those patients with a clinically relevant 
deficit (23).
For the purposes of this report, we used ClinicalTrials.gov 
to identify randomized, double-blind, placebo-controlled, 
add-on pharmacotherapy trials conducted in patients with 
a diagnosis of schizophrenia, in which a paper-and-pencil 
or computerized cognitive task (or battery) was specified as 
a primary outcome measure. These study designs are widely 
recognized as the “gold standard” for evidence generation and 
are recommended by the National Institute of Mental Health 
(NIMH) MATRICS panel for use in CIAS trials (28). While 
this may not have provided an exhaustive list of all CIAS trials 
that have been conducted, it does provide a useful snapshot 
of contemporary methodological practices in this field, 
particularly for major commercial studies. We attempted to 
identify corresponding published literature for all trials in 
an effort to verify details listed on ClinicalTrials.gov (further 
information was found for 41 (47.1%) of the included trials). We 
excluded Phase 1 trials, which typically focus on establishing 
the safety of a compound while looking at potential efficacy 
signals across a range of clinical and symptomatic measures, 
though screening for cognitive dysfunction among patients 
included in these early phase studies may also be useful when 
attempting to detect a hypothesized pro-cognitive effect of a 
novel compound.
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In conclusion, this paper highlights that purposive screening 
for cognitive impairment among patients with schizophrenia 
could increase statistical power to detect pro-cognitive 
treatment effects in clinical trials. While the focus of this 
article has been on pharmacotherapy studies, this could also 
have implications for other forms of therapeutic interventions. 
Further post hoc analyses of completed trials could help to 
shed further light on this hypothesis and ultimately aid in the 
development of effective treatments for this area of significant 
unmet clinical need.
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